Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2022; 10(36): 13264-13273
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13264
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13264
Oral higher dose prednisolone to prevent stenosis after endoscopic submucosal dissection for early esophageal cancer
Sheng-Gang Zhan, Ben-Hua Wu, De-Feng Li, Jun Yao, Zheng-Lei Xu, Ding-Guo Zhang, Rui-Yue Shi, Yan-Hui Tian, Li-Sheng Wang, Department of Gastroenterology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China
Author contributions: Zhan SG and Wang LS were responsible for the design of the study and reviewed the manuscript; Zhan SG, Wu BH, Li DF, and Yao J extracted the data; Zhan SG, Xu ZL, Zhang DG, Shi RY, and Tian YH performed the data analysis; Zhan GS and Wang LS were responsible for revising the manuscript; All authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Ethics Committee of Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital (Approval No. LL-KY-2022150-02).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Sheng Wang, PhD, Doctor, Department of Gastroenterology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, 1017 Dongmen North Road, Shenzhen 518020, Guangdong Province, China. wangls168@163.com
Received: August 28, 2022
Peer-review started: August 28, 2022
First decision: October 5, 2022
Revised: October 22, 2022
Accepted: December 5, 2022
Article in press: December 5, 2022
Published online: December 26, 2022
Peer-review started: August 28, 2022
First decision: October 5, 2022
Revised: October 22, 2022
Accepted: December 5, 2022
Article in press: December 5, 2022
Published online: December 26, 2022
Core Tip
Core Tip: Esophageal stenosis is one of the main complications of endoscopic submucosal dissection (ESD) for the remedy of large-area superficial esophageal squamous cell carcinoma and precancerous lesions (≥ 3/4 of the lumen). Oral prednisone (30 mg/d) is one of the most commonly used treatment measures to prevent postoperative stenosis after esophageal ESD; however, several studies have drawn inconsistent conclusions. For the first time, we took a higher dose of prednisone (50 mg/d) orally to prevent esophageal stenosis after esophageal ESD and no stenosis occurred in 14 patients, meanwhile, no significant glucocorticoid-related adverse events occurred.